TY - JOUR AU - Hallek, M. PY - 2017 DA - 2017// TI - Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment JO - Am J Hematol VL - 92 UR - https://doi.org/10.1002/ajh.24826 DO - 10.1002/ajh.24826 ID - Hallek2017 ER - TY - JOUR AU - Hallek, M. AU - Cheson, B. D. AU - Catovsky, D. AU - Caligaris-Cappio, F. AU - Dighiero, G. AU - Döhner, H. PY - 2018 DA - 2018// TI - iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-09-806398 DO - 10.1182/blood-2017-09-806398 ID - Hallek2018 ER - TY - JOUR AU - Buske, C. AU - Hutchings, M. AU - Ladetto, M. AU - Goede, V. AU - Mey, U. AU - Soubeyran, P. PY - 2018 DA - 2018// TI - ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma JO - Ann Oncol Off J Eur Soc Med Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx413 DO - 10.1093/annonc/mdx413 ID - Buske2018 ER - TY - JOUR AU - Fischer, K. AU - Hallek, M. PY - 2017 DA - 2017// TI - Optimizing frontline therapy of CLL based on clinical and biological factors JO - Hematol Am Soc Hematol Educ Program VL - 2017 UR - https://doi.org/10.1182/asheducation-2017.1.338 DO - 10.1182/asheducation-2017.1.338 ID - Fischer2017 ER - TY - JOUR AU - Tournilhac, O. AU - Garff-Tavernier, M. L. AU - Tabrizi, R. AU - Nguyen-Quoc, S. AU - Legrand-Izadifar, F. AU - Combes, P. PY - 2017 DA - 2017// TI - RIC allogeneic stem cell transplantation for high risk CLL followed by preemptive MRD-based immunointervention - final results from the phase II ICLL03 Ricac-Pmm trial (FILO - SFGM-TC French intergroup) JO - Blood. VL - 130 ID - Tournilhac2017 ER - TY - JOUR AU - Gribben, J. G. PY - 2018 DA - 2018// TI - How and when I do allogeneic transplant in CLL JO - Blood. VL - 132 UR - https://doi.org/10.1182/blood-2018-01-785998 DO - 10.1182/blood-2018-01-785998 ID - Gribben2018 ER - TY - JOUR AU - June, C. H. AU - O’Connor, R. S. AU - Kawalekar, O. U. AU - Ghassemi, S. AU - Milone, M. C. PY - 2018 DA - 2018// TI - CAR T cell immunotherapy for human cancer JO - Science. VL - 359 UR - https://doi.org/10.1126/science.aar6711 DO - 10.1126/science.aar6711 ID - June2018 ER - TY - JOUR AU - Porter, D. L. AU - Levine, B. L. AU - Kalos, M. AU - Bagg, A. AU - June, C. H. PY - 2011 DA - 2011// TI - Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa1103849 DO - 10.1056/NEJMoa1103849 ID - Porter2011 ER - TY - JOUR AU - Brentjens, R. J. AU - Rivière, I. AU - Park, J. H. AU - Davila, M. L. AU - Wang, X. AU - Stefanski, J. PY - 2011 DA - 2011// TI - Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias JO - Blood. VL - 118 UR - https://doi.org/10.1182/blood-2011-04-348540 DO - 10.1182/blood-2011-04-348540 ID - Brentjens2011 ER - TY - JOUR AU - Kalos, M. AU - Levine, B. L. AU - Porter, D. L. AU - Katz, S. AU - Grupp, S. A. AU - Bagg, A. PY - 2011 DA - 2011// TI - T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia JO - Sci Transl Med VL - 3 UR - https://doi.org/10.1126/scitranslmed.3002842 DO - 10.1126/scitranslmed.3002842 ID - Kalos2011 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Dudley, M. E. AU - Feldman, S. A. AU - Wilson, W. H. AU - Spaner, D. E. AU - Maric, I. PY - 2012 DA - 2012// TI - B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells JO - Blood. VL - 119 UR - https://doi.org/10.1182/blood-2011-10-384388 DO - 10.1182/blood-2011-10-384388 ID - Kochenderfer2012 ER - TY - JOUR AU - Cruz, C. R. Y. AU - Micklethwaite, K. P. AU - Savoldo, B. AU - Ramos, C. A. AU - Lam, S. AU - Ku, S. PY - 2013 DA - 2013// TI - Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2013-06-506741 DO - 10.1182/blood-2013-06-506741 ID - Cruz2013 ER - TY - JOUR AU - Kochenderfer, J. N. AU - Dudley, M. E. AU - Kassim, S. H. AU - Somerville, R. P. T. AU - Carpenter, R. O. AU - Stetler-Stevenson, M. PY - 2015 DA - 2015// TI - Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2025 DO - 10.1200/JCO.2014.56.2025 ID - Kochenderfer2015 ER - TY - JOUR AU - Porter, D. L. AU - Hwang, W. -. T. AU - Frey, N. V. AU - Lacey, S. F. AU - Shaw, P. A. AU - Loren, A. W. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac5415 DO - 10.1126/scitranslmed.aac5415 ID - Porter2015 ER - TY - JOUR AU - Fraietta, J. A. AU - Beckwith, K. A. AU - Patel, P. R. AU - Ruella, M. AU - Zheng, Z. AU - Barrett, D. M. PY - 2016 DA - 2016// TI - Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-11-679134 DO - 10.1182/blood-2015-11-679134 ID - Fraietta2016 ER - TY - JOUR AU - Brudno, J. N. AU - Somerville, R. P. T. AU - Shi, V. AU - Rose, J. J. AU - Halverson, D. C. AU - Fowler, D. H. PY - 2016 DA - 2016// TI - Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.5929 DO - 10.1200/JCO.2015.64.5929 ID - Brudno2016 ER - TY - JOUR AU - Ramos, C. A. AU - Savoldo, B. AU - Torrano, V. AU - Ballard, B. AU - Zhang, H. AU - Dakhova, O. PY - 2016 DA - 2016// TI - Clinical responses with T lymphocytes targeting malignancy-associated κ light chains JO - J Clin Invest VL - 126 UR - https://doi.org/10.1172/JCI86000 DO - 10.1172/JCI86000 ID - Ramos2016 ER - TY - JOUR AU - Turtle, C. J. AU - Hay, K. A. AU - Hanafi, L. -. A. AU - Li, D. AU - Cherian, S. AU - Chen, X. PY - 2017 DA - 2017// TI - Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.72.8519 DO - 10.1200/JCO.2017.72.8519 ID - Turtle2017 ER - TY - JOUR AU - Geyer, M. B. AU - Rivière, I. AU - Sénéchal, B. AU - Wang, X. AU - Wang, Y. AU - Purdon, T. J. PY - 2018 DA - 2018// TI - Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy JO - Mol Ther J Am Soc Gene Ther VL - 26 UR - https://doi.org/10.1016/j.ymthe.2018.05.018 DO - 10.1016/j.ymthe.2018.05.018 ID - Geyer2018 ER - TY - JOUR AU - Gauthier, J. AU - Hirayama, A. V. AU - Hay, K. A. AU - Li, D. AU - Lymp, J. AU - Sheih, A. PY - 2018 DA - 2018// TI - Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and/or refractory CLL JO - Blood. VL - 132 ID - Gauthier2018 ER - TY - JOUR AU - Gill, S. I. AU - Vides, V. AU - Frey, N. V. AU - Metzger, S. AU - O’Brien, M. AU - Hexner, E. PY - 2018 DA - 2018// TI - Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate JO - Blood. VL - 132 ID - Gill2018 ER - TY - JOUR AU - Siddiqi, T. AU - Soumerai, J. D. AU - Wierda, W. G. AU - Dubovsky, J. A. AU - Gillenwater, H. H. AU - Gong, L. PY - 2018 DA - 2018// TI - Rapid MRD-negative responses in patients with relapsed/refractory CLL treated with Liso-Cel, a CD19-directed CAR T-cell product: preliminary results from transcend CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib JO - Blood. VL - 132 ID - Siddiqi2018 ER - TY - JOUR AU - Fraietta, J. A. AU - Lacey, S. F. AU - Orlando, E. J. AU - Pruteanu-Malinici, I. AU - Gohil, M. AU - Lundh, S. PY - 2018 DA - 2018// TI - Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia JO - Nat Med VL - 24 UR - https://doi.org/10.1038/s41591-018-0010-1 DO - 10.1038/s41591-018-0010-1 ID - Fraietta2018 ER - TY - JOUR AU - Giordano Attianese, G. M. P. AU - Marin, V. AU - Hoyos, V. AU - Savoldo, B. AU - Pizzitola, I. AU - Tettamanti, S. PY - 2011 DA - 2011// TI - In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor JO - Blood. VL - 117 UR - https://doi.org/10.1182/blood-2010-10-311845 DO - 10.1182/blood-2010-10-311845 ID - Giordano Attianese2011 ER - TY - JOUR AU - Faitschuk, E. AU - Hombach, A. A. AU - Frenzel, L. P. AU - Wendtner, C. -. M. AU - Abken, H. PY - 2016 DA - 2016// TI - Chimeric antigen receptor T cells targeting fc μ receptor selectively eliminate CLL cells while sparing healthy B cells JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2016-01-692046 DO - 10.1182/blood-2016-01-692046 ID - Faitschuk2016 ER - TY - JOUR AU - Berger, C. AU - Sommermeyer, D. AU - Hudecek, M. AU - Berger, M. AU - Balakrishnan, A. AU - Paszkiewicz, P. J. PY - 2015 DA - 2015// TI - Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-14-0163 DO - 10.1158/2326-6066.CIR-14-0163 ID - Berger2015 ER - TY - JOUR AU - Zhao, Z. AU - Condomines, M. AU - Stegen, S. J. C. AU - Perna, F. AU - Kloss, C. C. AU - Gunset, G. PY - 2015 DA - 2015// TI - Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells JO - Cancer Cell VL - 28 UR - https://doi.org/10.1016/j.ccell.2015.09.004 DO - 10.1016/j.ccell.2015.09.004 ID - Zhao2015 ER - TY - JOUR AU - Hoffmann, J. -. M. AU - Schubert, M. -. L. AU - Wang, L. AU - Hückelhoven, A. AU - Sellner, L. AU - Stock, S. PY - 2017 DA - 2017// TI - Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01956 DO - 10.3389/fimmu.2017.01956 ID - Hoffmann2017 ER - TY - JOUR AU - Mueller, K. T. AU - Maude, S. L. AU - Porter, D. L. AU - Frey, N. AU - Wood, P. AU - Han, X. PY - 2017 DA - 2017// TI - Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2017-06-786129 DO - 10.1182/blood-2017-06-786129 ID - Mueller2017 ER - TY - JOUR AU - Riches, J. C. AU - Davies, J. K. AU - McClanahan, F. AU - Fatah, R. AU - Iqbal, S. AU - Agrawal, S. PY - 2013 DA - 2013// TI - T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2012-09-457531 DO - 10.1182/blood-2012-09-457531 ID - Riches2013 ER - TY - JOUR AU - Dubovsky, J. A. AU - Beckwith, K. A. AU - Natarajan, G. AU - Woyach, J. A. AU - Jaglowski, S. AU - Zhong, Y. PY - 2013 DA - 2013// TI - Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2013-06-507947 DO - 10.1182/blood-2013-06-507947 ID - Dubovsky2013 ER - TY - JOUR AU - Yin, Q. AU - Sivina, M. AU - Robins, H. AU - Yusko, E. AU - Vignali, M. AU - O’Brien, S. PY - 2017 DA - 2017// TI - Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia JO - J Immunol Baltim Md 1950 VL - 198 ID - Yin2017 ER - TY - JOUR AU - Long, M. AU - Beckwith, K. AU - Do, P. AU - Mundy, B. L. AU - Gordon, A. AU - Lehman, A. M. PY - 2017 DA - 2017// TI - Ibrutinib treatment improves T cell number and function in CLL patients JO - J Clin Invest VL - 127 UR - https://doi.org/10.1172/JCI89756 DO - 10.1172/JCI89756 ID - Long2017 ER - TY - JOUR AU - Neelapu, S. S. AU - Locke, F. L. AU - Bartlett, N. L. AU - Lekakis, L. J. AU - Miklos, D. B. AU - Jacobson, C. A. PY - 2017 DA - 2017// TI - Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMoa1707447 DO - 10.1056/NEJMoa1707447 ID - Neelapu2017 ER - TY - JOUR AU - Fraietta, J. A. AU - Nobles, C. L. AU - Sammons, M. A. AU - Lundh, S. AU - Carty, S. A. AU - Reich, T. J. PY - 2018 DA - 2018// TI - Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells JO - Nature. VL - 558 UR - https://doi.org/10.1038/s41586-018-0178-z DO - 10.1038/s41586-018-0178-z ID - Fraietta2018 ER -